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Neurobiology of Disease
Systemic Inflammatory Stimulus Potentiates the Acute
Phase and CXC Chemokine Responses to Experimental
Stroke and Exacerbates Brain Damage via Interleukin-1- and
Neutrophil-Dependent Mechanisms
BarryW. McColl, Nancy J. Rothwell, and Stuart M. Allan
Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom
Systemic inflammatory stimuli, such as infection, increase the risk of stroke and are associated with poorer clinical outcome. The
mechanisms underlying the impact of systemic inflammatory stimuli on stroke are not well defined. We investigated the impact of
systemic inflammationon experimental stroke andpotentialmechanisms involved. Focal cerebral ischemiawas inducedby intraluminal
filament occlusion of the middle cerebral artery (MCAo). Brain damage and neurological deficit 24 h after MCAo were exacerbated by
systemic lipopolysaccharide (LPS) administration. This exacerbation was critically dependent on interleukin (IL)-1, because coadmin-
istration of IL-1 receptor antagonist abolished the effect of LPS on brain damage. Systemic administration of IL-1 increased ischemic
damage to a similar extent as LPS and also exacerbated brain edema. IL-1 markedly potentiated circulating levels of the acute phase
proteins, serum amyloid A and IL-6, and the neutrophil-selective CXC chemokines, KC and macrophage inflammatory protein-2. Neu-
trophil mobilization and cortical neutrophil infiltration were aggravated by IL-1 before changes in ischemic damage. Neutropenia
abolished the damaging effects of systemic IL-1. These data show for the first time that an acute systemic inflammatory stimulus is
detrimental to outcome after experimental stroke and highlight IL-1 as a critical mediator in this paradigm. Our data suggest IL-1-
inducedpotentiationofneutrophilmobilizationviaCXCchemokine induction is aputativemechanismunderlying this effect. Our results
may help to explain the poorer outcome in stroke patients presenting with infection and may have implications for neurodegenerative
diseases involving neurovascular alterations, such as Alzheimer’s disease, in which systemic inflammation can modulate disease
progression.
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Introduction
It is well established that local inflammatory processes in the
brain contribute to the damage caused by acute brain injury and
the progression of neurodegenerative disease. In contrast, the
role of systemic inflammatory processes has been poorly investi-
gated, although growing evidence suggests that the incidence of,
and response to, acute brain injury and the progression of several
neurodegenerative diseases are modulated by systemic inflam-
matory events such as infection (Emsley and Tyrrell, 2002; Perry,
2004). In particular, considerable clinical data indicate that acute
and chronic systemic infection are risk factors for stroke and are
associated with less favorable clinical outcome (Grau et al.,
1995a,b; Smeeth et al., 2004; Palasik et al., 2005). The mecha-
nisms underlying the effects of systemic inflammation on CNS
injury are poorly defined.
The induction of systemic innate immune responses after
stroke that also occur during the host defense response to infec-
tion may serve as a point of convergence when these insults are
coincident. Stroke elicits a systemic acute phase response and is
associated with increased levels of circulating cytokines, acute
phase reactants, and elevated neutrophil and total leukocyte
counts, which correlate with poor clinical outcome (Muir et al.,
1999; Emsley et al., 2003; Smith et al., 2004; Waje-Andreassen et
al., 2005; Rallidis et al., 2006). A recent study further highlighted
the marked activation of systemic immune pathways after exper-
imental stroke, including induction of cytokines and chemokines
in peripheral lymphoid organs (Offner et al., 2006).
The proinflammatory cytokine, interleukin (IL)-1, is an im-
portant mediator of acute brain injury (Allan et al., 2005) and a
key regulator of inflammation during the host defense response.
IL-1mediates several of the physiological and behavioral changes
in response to a systemic inflammatory challenge induced by the
bacterial endotoxin, lipopolysaccharide (LPS), or turpentine
(Long et al., 1990; Luheshi et al., 1996, 1997; Miller et al., 1997b).
IL-1 may act by inducing the expression of an array of down-
stream mediators, several of which are pertinent to the systemic
inflammatory response after stroke, in particular IL-6 and che-
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mokines (Miller et al., 1997b; Cartmell et al., 2000; Calkins et al.,
2002). Treatment of acute stroke patients with the IL-1 receptor
antagonist (IL-1RA) markedly attenuates the elevated plasma
IL-6 and C-reactive protein levels and neutrophil counts (Emsley
et al., 2005).
The objective of the present study was to investigate the im-
pact of systemic inflammation on experimental stroke and to
assess the role of IL-1 and downstreammediators in this context.
We first show that peripheral LPS challenge exacerbates brain
injury after focal cerebral ischemia, an effect critically dependent
on IL-1. We then demonstrate that peripheral IL-1 challenge has
pathological effects similar to LPS, acting via the induction of
neutrophil-selective CXC chemokines and a neutrophil-
dependent mechanism.
Materials andMethods
Mice. All experiments were performed on 10- to 12-week-old (25–30 g)
C57BL/6J mice (Harlan-Olac, Bicester, UK) under appropriate United
Kingdom Home Office personal and project licenses and adhered to
regulations as specified in the Animals (Scientific Procedures) Act
(1986).
Focal cerebral ischemia. Focal ischemia was induced by transient (30
min) middle cerebral artery occlusion (MCAo) using a modification of
the intraluminal filament technique originally described (Longa et al.,
1989). Core body temperature was regulated at 37  0.5°C throughout
the procedure by a feedback-controlled heating blanket. Under halo-
thane anesthesia (30% O2/70% N2O), the carotid arteries were exposed
and a 6-0 nylon monofilament (Dermalon) with 2 mm tip (180 m
diameter) coated in thermo-melting glue (Jet Melt) was introduced into
the external carotid artery and advanced 9mm along the internal carotid
artery (ICA) until occluding the origin of the MCA. After 30 min, the
filament was withdrawn to establish reperfusion. Sham-operated mice
underwent the same procedure except the filament was advanced along
the ICA, and then immediately withdrawn. Mortality rate was15% in
all groups except where stated.
Drug administration. All treatments were administered in a blinded
manner by intraperitoneal injection in a volume of 100 l/25 g. LPS
serotype 0127:B8 (Sigma, St. Louis,MO; 100g/kg in 0.9% sterile saline)
or vehicle (0.9% sterile saline) was administered 30 min before the onset
of MCAo. Recombinant human IL-1RA [National Institute for Biologi-
cal Standards andControls (NIBSC), Potters Bar,Hertfordshire, UK; 100
mg/kg in saline] or vehicle were coadministered with LPS 30 min before
MCAo, and additional injections were given 1 and 4 h after MCAo.
Recombinant IL-1 (NIBSC; biological activity, 100,000 IU/g) diluted
in vehicle (0.5% endotoxin-free bovine serum albumin in sterile PBS) at
indicated doses, or vehicle was administered at the onset of MCAo. To
deplete neutrophils, mice received three injections of rabbit anti-
polymorphonuclear leukocyte (PMN) IgG (Accurate Scientific, West-
bury, NY; 2 mg/kg) or rabbit IgG as control at the same dose diluted in
sterile saline. One injection was given per day for 3 d before MCAo.
Assessment of neurological deficit. Neurological status was assessed
blinded to drug treatment and according to a neurological grading score
of increasing severity of deficit (Bederson et al., 1986): 0, no observable
deficit; 1, torso flexion to right; 2, spontaneous circling to right; 3, lean-
ing/falling to right; 4, no spontaneous movement.
Tissue processing. For measurement of ischemic damage and cerebral
edema, brains were removed and snap-frozen in chilled isopentane. For
immunohistochemistry, mice were perfused transcardially with 0.9%
saline followed by 4% paraformaldehyde. Brains were removed, post-
fixed, cryoprotected (15% sucrose), and frozen. For all experiments, sec-
tions (20 m) were cut on a cryostat (Leica Microsystems, Nussloch,
Germany) and stored at 20°C. Plasma was extracted from anticoagu-
lated (sodium citrate) blood samples obtained by cardiac puncture.
Measurement of ischemic brain damage and edema. Coronal brain sec-
tions at 400m intervals were stainedwith cresyl violet (Sigma). Areas of
ischemic damage at each coronal level were delineated and the volume of
ischemic damage was derived from the sum of all areas of damage mul-
tiplied by the distance between each section (0.4 mm). The volume of
damage was corrected for edema as described previously (Lin et al.,
1993). The extent of edema was calculated by subtracting the volume of
the hemisphere contralateral toMCAo from the volume of the ipsilateral
hemisphere and expressing the difference as a percentage of the con-
tralateral hemisphere. Ischemic damage and edema were measured
blinded to drug treatment.
Circulating leukocyte counts.Terminal cardiac blood sampleswere cen-
trifuged at 700 g and plasma aspirated. Erythrocytes were lysed and a
leukocyte differential determined fromWright–Giemsa-stained smears.
Immunohistochemistry. Endogenous peroxidase activity was blocked
with 0.3%H2O2 in methanol and nonspecific binding sites were blocked
with 10% normal serum (Vector Laboratories, Burlingame, CA). Sec-
tions were incubated in primary antibody solution [1:500 anti-
neutrophil serum (MBS-1) (gift from V. H. Perry, University of
Southampton, Southampton, UK) in 5%blocking solution] overnight at
4°C followed by appropriate biotinylated secondary antibody (Vector;
1:200 in PBS). Primary antibody incubation was omitted for assessment
of blood–brain barrier (BBB) disruption using biotinylated anti-mouse
IgG. Sections were then incubated in Vectastain ABC solution (Vector)
and color was developed by diaminobenzidine incubation (Vector). Ce-
rebral neutrophil infiltration was quantified in a blinded manner by
counting the number of MBS-immunopositive cells in three areas of the
cortex (somatosensory, insular, piriform) or striatum (dorsal, lateral,
ventral) at two coronal levels (0.2 and0.5 mm relative to bregma). The
mean was calculated from the six fields in the cortex or striatum and
adjusted to express as mean number of cells per square millimeter.
ELISA. Plasma IL-6, KC, macrophage inflammatory protein-2
(MIP-2) (Duoset; R & D Systems, Minneapolis, MN), and serum amy-
loid A (SAA) (Biosource, Camarillo, CA) concentrations were deter-
mined by ELISA according to manufacturer’s instructions.
Statistical analysis. For all analyses, n  6–8, except where stated.
Parametric data were analyzed using Student’s t test for single compari-
sons and one-way ANOVA followed by Student’s t test with Bonferroni’s
correction or Dunnett’s test for multiple comparisons. Nonparametric
data were analyzed using Kruskal–Wallis test followed by Dunn’s test for
multiple comparisons.
Results
Acute systemic inflammatory challenge worsens outcome
after experimental stroke
To determine the effect of a systemic inflammatory stimulus on
acute ischemic brain damage, we administered bacterial endo-
toxin (LPS) intraperitoneally 30 min before MCAo and assessed
the extent of ischemic damage and neurological deficit 24 h post-
MCAo. LPS caused a 150% increase in the volume of ischemic
damage compared with vehicle treatment ( p  0.01) (Fig. 1A),
which wasmostly attributable to exacerbation of cortical damage
(Fig. 1B), and significantly increased the severity of neurological
deficit ( p 0.05) (Fig. 1C).
LPS induces several mediators, including IL-1, via activation
of Toll-like receptors (TLRs). We tested the hypothesis that IL-1
mediates the effects of LPS on ischemic brain damage by coad-
ministering LPS with the specific IL-1RA. Coadministration of
IL-1RA significantly attenuated ( p 0.05) the LPS-induced ex-
acerbation of damage by 60% and improved neurological status
(Fig. 1A). To further examine the specific role of systemic IL-1 in
the absence of potentially diverse and confounding actions of
LPS, recombinant IL-1 was administered intraperitoneally and
ischemic damage and neurological deficit were assessed 24 h after
MCAo. IL-1 (10 or 100 IU) significantly exacerbated (150%)
the volume of ischemic damage comparedwith vehicle treatment
( p  0.05) (Fig. 2A) and significantly increased the severity of
neurological deficit (10 IU; p 0.05) (Fig. 2B).Mortality ratewas
60% in mice treated with the high dose (100 IU) of IL-1. All
subsequent experimentswere conducted using the lower dose (10
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Figure1. Systemic LPS exacerbates ischemic brain damage via an IL-1-dependent pathway.
LPSwas administered systemically, and the extent of ischemic damage and neurological deficit
was assessed 24 h after MCAo. A, LPS significantly increased the volume of ischemic damage.
Coadministration of IL-1RA attenuated the effect of LPS. **p 0.01 versus vehicle (veh); #p
0.05 versus LPS, one-way ANOVA followed by Student’s t testwith Bonferroni’s correction. Data
are presented as mean SEM. B, Representative cresyl violet-stained sections illustrate the
distribution of ischemic damage after MCAo in vehicle- or LPS-treated mice. C, LPS worsened
neurological outcomeandcoadministrationof IL-1RA reduced thenumberofmicewitha severe
neurological deficit (score, 3). *p 0.05 versus vehicle, Kruskal–Wallis test followedbyDunn’s
multiple-comparison test. Bars showmedian. n 6–7 per group.
Figure 2. Dose-dependent exacerbation of ischemic brain damage by systemic IL-1. Re-
combinant IL-1was administered systemically at the onset of MCAo, and the extent of isch-
emic damage and neurological deficit was assessed 24 h after MCAo. A, IL-1 induced a dose-
dependent exacerbationof ischemicdamage. **p0.01versus vehicle (veh), one-wayANOVA
followed by Dunnett’s multiple-comparison test. Data are presented as mean SEM. B, Neu-
rological deficit was exacerbated in a dose-dependent manner by IL-1. *p 0.05 versus
vehicle, Kruskal–Wallis test followed by Dunn’s multiple-comparison test. Bars show median.
C, IL-1 exacerbated damage in cerebral cortex but not in the striatum. **p 0.01 versus
vehicle, Student’s t test. Data are presented asmean SEM; n 6 per group except for IL-1
(100 IU)-treated group (n 3) because of high mortality rate (60%).
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IU) of IL-1, which is similar to the concentration and biological
activity of IL-1 induced locally by LPS (100 g/kg) injection
(Miller et al., 1997a; Cartmell et al., 2000). Ischemic damage was
primarily striatal in distribution in vehicle-treated mice, with
IL-1 (10 IU) increasing ischemic damage predominantly in the
cerebral cortex ( p 0.01) (Fig. 2C).
Systemic IL-1 exacerbates brain edema and blood–brain
barrier permeability before ischemic damage
We next determined the effects of a systemic IL-1 challenge on
the temporal progression of ischemic damage, edema, and BBB
breakdown. There were no differences in the extent of ischemic
damage 4 and 8 h after MCAo when damage was confined to the
striatum after vehicle or IL-1 treatment (Fig. 3A). There was
clear infarction in striatal and cortical tissue 24 h after MCAo,
and IL-1 treatment resulted in amarked increase in the extent of
damage ( p 0.01) (Fig. 3A), consistent with the data shown in
Figure 1.
Edema was evident in the occluded hemisphere in both
vehicle- and IL-1-treated mice, and the extent of edema in-
creased as reperfusion progressed (Fig. 3B). IL-1 significantly
exacerbated edema 8 and 24 h after reperfusion ( p  0.05). Ef-
fects of IL-1 on edema were evident, therefore, before overt
alterations in ischemic damage.
Increased permeability of the BBB contributes to vasogenic
brain edema. We therefore assessed whether IL-1 exacerbated
BBB disruption using IgG immunohistochemistry. Parenchymal
IgG immunoreactivity reflects areas of disrupted BBB because
IgG cannot cross the intact BBB. Marked increases in the distri-
bution and intensity of IgG immunoreactivity were evident in
IL-1-treated mice 8 and 24 h after MCAo (Fig. 3C), suggesting
IL-1-induced escalation of early and ongoing BBB disruption
after cerebral ischemia. Such an early exacerbation of BBB per-
meability is consistent with a causative role in the development of
ischemic damage. There was no IgG immunostaining of brain
tissue in sham-operated mice after vehicle or IL-1 treatment.
Systemic IL-1 potentiates the postischemic acute
phase response
The temporal profile of the IL-1-induced exacerbation of dam-
age indicated the involvement of mechanisms progressing over
several hours, consistent with the induction of peripheral inflam-
matory processes. We next determined whether a systemic IL-1
challenge affected themagnitude of the postischemic acute phase
response, a key indicator of the extent of peripheral inflammation
and highly correlative with prognosis in stroke patients. IL-1
greatly potentiated the plasma concentration of the acute-phase
reactant, SAA, 4 h after MCAo, inducing a significant eightfold
increase in SAA compared with vehicle treatment (Fig. 4A). The
magnitude of the increase 4 h after MCAo indicated synergism
between the ischemic and IL-1 challenges. SAA levels declined
as reperfusion progressed. Plasma IL-6 levels were markedly in-
creased 4 h after MCAo and declined as reperfusion progressed
(Fig. 4B). IL-1 potentiated the plasma IL-6 concentration at all
time points after MCAo, and these differences were statistically
significant 4 and 8 h after MCAo ( p  0.05) (Fig. 4B). The
magnitude of the IL-1-induced elevations in plasma IL-6 after
MCAo indicated synergistic effects between IL-1 and ischemic
challenges.
Figure 3. Systemic IL-1 potentiates brain edema and blood–brain barrier permeability
after MCAo. Recombinant IL-1was administered systemically at the onset of MCAo, and the
temporal progression of ischemic damage, brain edema, and BBB disruption were assessed. A,
IL-1 significantly exacerbated ischemic damage 24h afterMCAobut not 4 and 8h afterMCAo.
B, IL-1 significantly increased the extent of edema 8 and 24 h after MCAo. C, Representative
brain sections immunostained for IgG. IL-1markedly increased the intensity and distribution
of IgG immunoreactivity 8 and 24 h after MCAo, indicating potentiation of BBB disruption by
IL-1. *p 0.05, **p 0.01 versus vehicle (veh), Student’s t test. Data are presented as
mean SEM. Scale bar, 1 mm. n 6–8 per group.
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Systemic IL-1 potentiates postischemic neutrophilia and
cortical neutrophil infiltration
Neutrophils respond to injury and/or infection bymigrating into
inflamed tissuewithin hours of the insult.Wenext testedwhether
a systemic IL-1 challenge potentiated the postischemic mobili-
zation of neutrophils and their infiltration into the brain. In
vehicle-treated mice, MCAo induced an increase in the number
of circulating PMNs by over 30% comparedwith the preischemic
value 8 and 24 h after MCAo with the peak neutrophilia 8 h after
MCAo (Fig. 5A, Table 1). IL-1 treatment significantly potenti-
ated the number of circulating PMNs 8 h afterMCAo ( p 0.05)
and to a lesser extent 4 and 24 h after MCAo. IL-1 did not
significantly alter the number of circulating monocytes or lym-
phocytes (Table 1).
Marked accumulation of neutrophils in the brain was ob-
served in vehicle- and IL-1-treated mice at all time points as-
sessed after ischemia. Intravascular and marginating (Fig. 5B)
and parenchymal (Fig. 5C) neutrophils were observed consis-
tently in the striatum and cerebral cortex of the occluded hemi-
sphere. Neutrophils were more abundant and more extensively
distributed in IL-1-treated mice (Fig. 5E,G) compared with
vehicle-treated mice (Fig. 5D,F), particularly in the cortex 8 h
(Fig. 5D,E) and 24 h (Fig. 5F,G) after MCAo. Neutrophils were
rarely observed after MCAo in the contralateral hemisphere and
sham-operated mice displayed few, if any, neutrophils.
Quantification of neutrophil accumulation in the striatum
revealed a general decline in numbers as reperfusion progressed
but no significant differences between vehicle- and IL-1-treated
mice (Fig. 5H). In contrast, neutrophil accumulation in the cor-
tex increased as reperfusion progressed in both vehicle- and IL-
1-treated mice. IL-1 caused a significant increase in the num-
ber of neutrophils at all time points (4 h, p 0.05; 8 h, p 0.05;
24 h, p 0.01) (Fig. 5H) and resulted in an intense accumulation
at 24 h.
Systemic IL-1 potentiates postischemic plasma CXC
chemokine levels
We next assessed the impact of systemic IL-1 on circulating
levels of CXCL1 (KC) and CXCL2 (MIP-2), the major chemo-
kines that mobilize and direct migration of neutrophils in mice.
In vehicle-treated mice, MCAo induced a fivefold increase in
plasma KC concentration 4 h after MCAo (compared with
sham). IL-1 induced a significant 10-fold potentiation of
plasma KC concentration 4 h after MCAo ( p 0.01) (Fig. 6A).
There was also a significant IL-1-induced potentiation of
plasma KC 8 h after MCAo ( p  0.05), although levels were
reduced markedly compared with 4 h. The magnitude of the
IL-1-induced potentiation of plasma KC after MCAo indicated
a synergistic interaction between the IL-1 and ischemic chal-
lenges. Plasma MIP-2 concentration was also elevated 4 h after
MCAo and IL-1 significantly potentiated MIP-2 levels at this
time point ( p  0.01) (Fig. 6B). Similarly to KC, there was a
synergistic interaction between IL-1 and ischemic challenges on
plasma MIP-2 concentration 4 h after MCAo. At later time
points, MIP-2 concentration markedly subsided.
Neutrophils mediate the exacerbation of ischemic brain
damage by systemic IL-1
To directly test the hypothesis that neutrophils are important
cellular mediators of the pathological effects of a systemic IL-1
challenge, we depleted neutrophils using an anti-PMN
leukocyte-depleting antibody. The extent of neutrophil depletion
was90% ( p 0.001), and the depleting antibody had no effect
on other leukocyte populations (supplemental figure, available at
www.jneurosci.org as supplemental material). The number of
circulating PMNs was significantly reduced by 90% after
MCAo inPMN-depletedmice treatedwith vehicle ( p 0.001) or
IL-1 ( p 0.001) (Fig. 7A). Abundant neutrophil accumulation
in the cerebral cortex was observed after MCAo in response to
IL-1 treatment in nondepletedmice (Fig. 7B). In contrast, there
were few neutrophils observed after MCAo in response to IL-1
treatment in PMN-depleted mice (Fig. 7C). Quantification of
neutrophil numbers in the cerebral cortex demonstrated a signif-
icant attenuation of the IL-1-induced neutrophil infiltrate in
PMN-depleted mice ( p 0.05) (Fig. 7D).
The volume of ischemic damage 24 h after MCAo in PMN-
depleted mice challenged with systemic IL-1 was significantly
smaller ( p  0.05) compared with nondepleted mice in which
there was a threefold increase in damage compared with vehicle-
treated mice (Fig. 7E). This attenuation was the result of a reduc-
tion in cortical damage (Fig. 7F). PMN depletion also signifi-
Figure 4. Systemic IL-1 exacerbates the acute-phase response after MCAo. Plasma SAA
and IL-6 concentrations were measured by ELISA in mice administered vehicle (veh) or IL-1
systemically at the onset of MCAo. A, IL-1 significantly increased the concentration of plasma
SAA 4 h after MCAo. B, IL-1markedly increased the concentration of plasma IL-6 at all time
points after MCAo, although the change was statistically significant only 4 h after MCAo. nd,
Belowdetection limit. *p0.05 versus vehicle, Student’s t test. Data are presented asmean
SEM. n 6–8 per group.
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cantly reduced ( p  0.05) the severity of
neurological deficit in IL-1-challenged
mice (Fig. 7G). Depletion did not alter
ischemic damage or neurological deficit in
vehicle-treated mice.
Discussion
We demonstrate, for the first time, that a
systemic inflammatory stimulus, which
mimics aspects of infection, adversely af-
fects outcome after experimental stroke
and highlight a critical role for IL-1 inme-
diating this effect on brain injury. Our
data further implicate IL-1-induced CXC
chemokines and neutrophil mobilization
in this paradigm. Environmental factors,
such as infection, are increasingly recog-
nized as important modulators of the in-
cidence of stroke and functional recovery
(Emsley and Tyrrell, 2002). Infection may
also interact with conventional stroke risk
factors, such as atherosclerosis, to cooper-
atively modify stroke risk and outcome.
Our data suggest that systemic inflamma-
tory stimuli may act synergistically with
the ischemic challenge to markedly am-
plify systemic innate immune responses
leading to exacerbation of brain damage.
In this way, systemic inflammatory path-
ways could provide a point of convergence
and synergy when stroke is coincident
with an attendant inflammatory stimulus.
The molecular and cellular pathways
thatmediate the detrimental effects of sys-
temic inflammation on stroke are unclear.
Although LPS induces the synthesis and
release of multiple inflammatory media-
tors via TLR activation, the present data
strongly implicate a critical and nonre-
dundant function for IL-1 because coad-
ministration of IL-1RA significantly at-
tenuated the LPS-induced worsening of
ischemic damage and neurological deficit.
Consistent with this effect, systemic ad-
ministration of recombinant IL-1 exac-
erbated ischemic damage and neurologi-
cal deficit to a similar extent as LPS,
suggesting that peripheral IL-1 challenge
is a similar stimulus to LPS and further
supporting that IL-1 is the keymediator of
LPS in this brain injury paradigm. These
results parallel previous studies showing
that IL-1 is important for many host defense responses to sys-
temic LPS challenge (Long et al., 1990; Luheshi et al., 1996;Miller
et al., 1997b). It is likely that IL-1 was acting peripherally be-
cause levels were minimal in the circulation and undetectable in
the brain after intraperitoneal administration (data not shown).
In support of this, studies have shown that paracrine actions of
IL-1 in peripheral tissues, such as the induction of IL-6,mediate
LPS-induced fever (Miller et al., 1997a; Cartmell et al., 2000).
However, this would not exclude that peripheral IL-1may also
influence the formation of damage by inducing CNS expression
of cytokines and other inflammatorymediators via circulatory or
neural (vagal) routes. IL-1 is a known pyrogen under nonisch-
emic conditions, and elevated core body and brain temperature
are associated with poorer outcome after stroke (Busto et al.,
1987; Meden et al., 1994; Reith et al., 1996). However, previous
studies have shown that the neuropathological effects of IL-1
are dissociated from its pyrogenic actions (Loddick andRothwell,
1996; Stroemer and Rothwell, 1998). This may be explained by
the compromised perfusion and metabolic activity in ischemic
tissue that will reduce the influx and production of heat and
mitigate the pyrogenic effects of IL-1. Indeed, using a similar rat
model of stroke and magnetic resonance spectroscopy to mea-
Figure 5. Systemic IL-1 potentiates neutrophilia and cortical neutrophil infiltration afterMCAo.A, The number of circulating
PMNs was assessed in mice administered vehicle (veh) or IL-1 systemically at the onset of MCAo. IL-1 significantly increased
thenumber of circulatingPMNs8hafterMCAo. Thedotted line indicates pre-MCAovalue (vehicle and IL-1groups pooled).B–D,
Accumulation of neutrophils in the brain was assessed by anti-MBS-1 immunohistochemistry. Neutrophils were observed in the
cerebral vasculature (B) and brain parenchyma (C). Representative brain sections illustrate neutrophil accumulation in cerebral
cortex ipsilateral to MCAo 8 h (D, E) and 24 h (F, G) after MCAo. Marked increases in the number of neutrophils infiltrating into
cortical tissue were observed in IL-1-treated mice (E, G) compared with vehicle-treated mice (D, F ). H, IL-1 significantly
increased the number of neutrophils accumulating in the cerebral cortex 4, 8, and 24 h after MCAo. *p 0.05, **p 0.01 versus
vehicle, Student’s t test. Data are presented as mean SEM. Scale bars: A–D, 100m; E–G, 25m. n 6–8 per group.
4408 • J. Neurosci., April 18, 2007 • 27(16):4403–4412 McColl et al. • Systemic Inflammation and Experimental Stroke
sure brain temperature, we recently found that systemic IL-1
challenge actually reduced local brain temperature in ischemic
tissue during occlusion and early reperfusion (Parry-Jones et al.,
2006).
Our data provide comprehensive evidence that a systemic
IL-1 challenge worsens acute brain injury by exacerbating the
mobilization and infiltration of neutrophils into the ischemic
brain. Previous studies in the absence of a systemic inflammatory
stimulus, in which neutrophils have been depleted or their emi-
gration from the vasculature inhibited, have provided consider-
able evidence that neutrophils contribute to ischemic brain dam-
age (Chen et al., 1994; Connolly et al., 1996; Dawson et al., 1996;
Yenari et al., 1998; Beray-Berthat et al., 2003; Arumugam et al.,
2004), although there are also conflicting reports (Fassbender et
al., 2002; Maier et al., 2004). In the present study, IL-1 potenti-
ated the postischemic neutrophilia and accumulation of neutro-
phils in the cerebral cortex before alterations in brain damage.
Such a temporal and spatial pattern is consistent with a causative
role in the development of enhanced cortical injury and this was
supported by the marked attenuation of IL-1-induced cortical
damage by neutrophil depletion. Indeed, the contribution of
neutrophils to brain damage appears to be brain region specific
with a predominant role in the cortex (Yenari et al., 1998; Beray-
Berthat et al., 2003). This may reflect the more extensive vascu-
lature and greater perfusion of cortical tissue (cf. striatum) that
will promote neutrophil trafficking through this territory. Alter-
natively, more abundant cortical expression of mediators re-
quired for neutrophil extravasation (selectins, chemokines, ad-
hesion molecules) could determine the relative predominance of
cortical neutrophil accumulation. Neutrophils may promote the
conversion of vulnerable yet viable cortical tissue to infarction
through microvessel obstruction/thrombosis that compromises
reperfusion (del Zoppo et al., 1991; Ritter et al., 2000), produc-
tion of reactive oxygen species (ROS) causing oxidative stress
(Aizawa et al., 2006), and release of matrix metalloproteinases
that degrade components of the vascular basement membrane
and extracellular matrix (Asahi et al., 2001; Gidday et al., 2005).
This may account for themarkedly greater BBB permeability and
aggravated cerebral edema we observed in response to IL-1
challenge. These alterations have important clinical implications,
because raised intracranial pressure is a precarious consequence
of brain edema and a key determinant of outcome after ischemic
brain injury (Ayata and Ropper, 2002). It will be important to
further elucidate how the various aspects of neutrophil dynamics
(e.g., mobilization, adhesion/transmigration, release of toxic
mediators) contribute to the deleterious effects of systemic
inflammation, for example, by specifically inhibiting endothe-
lial–neutrophil interactions or preventing release of/inhibit-
ing neutrophil-derived proteases and ROS. Neutrophil and
total leukocyte counts were elevated in stroke patients pre-
senting with antecedent infection (Emsley et al., 2003). Al-
though it was not possible to assess the contribution of IL-1 to
the aggravated neutrophilia in these patients, a recent phase II
clinical trial in stroke patients demonstrated that IL-1RA al-
most completely abolished the stroke-induced neutrophilia
(Emsley et al., 2005). These clinical findings lend support to
the possibility that IL-1-induced potentiation of neutrophil
mobilization contributes to poorer outcome in stroke patients
with preexisting systemic inflammation.
Table 1. Effect of systemic IL-1 on circulating white blood cells after MCAo
Pre-MCAoa
4 h 8 h 24 h
Vehicle IL-1 Vehicle IL-1 Vehicle IL-1
Total WBCs/l 2228 117 1800 105 1900 148 1967 229 2586 385 1988 214 1825 43
PMNs/l 380 23 396 12 501 61 605 80 1081 138* 531 53 661 95
Monocytes/l 126 7 115 11 134 18 141 28 160 13 216 16 215 43
Lymphocytes/l 1722 93 1289 97 1265 142 1220 143 1345 286 1241 173 949 211
The number of circulating white blood cells was determined from cardiac blood in mice treated with vehicle or IL-1 at the onset of MCAo. WBC, White blood cell. *p 0.05 versus vehicle, Student’s t test. n 6–8 per group.
aVehicle and IL-1 groups pooled.
Figure 6. Systemic IL-1 potentiates circulating CXC chemokine levels after MCAo. Plasma
KC and MIP-2 concentrations were measured by ELISA in mice administered vehicle (veh) or
IL-1 systemically at the onset of MCAo. A, IL-1 significantly increased the concentration of
plasma KC 4 and 8 h after MCAo, although levels were generally lower than 8 h after MCAo. By
24 h after MCAo, KC concentrations had returned to baseline levels. B, IL-1 also significantly
increased the concentration of plasmaMIP-2 4 h afterMCAo but did not alter levels at any other
time point. nd, Below detection limit. *p 0.05, **p 0.01 versus vehicle, Student’s t test.
Data are presented as mean SEM. n 6–8 per group.
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Neutrophils are only weakly respon-
sive to IL-1, suggesting IL-1 stimulates
neutrophil mobilization indirectly. The
activation and migration of neutrophils
are regulated by CXC chemokines, small
peptides that bind G-protein-coupled re-
ceptors on the neutrophil surface and
stimulate their discharge from bone mar-
row and direct their local movement to
sites of injury and/or infection (Baggio-
lini, 1998; Campbell et al., 2005). In the
present study, the striking potentiation of
postischemic KC and MIP-2 levels may
account for the aggravated neutrophilia
and cortical neutrophil accumulation in-
duced by IL-1. The temporal profile of
the chemokine response was notable for
its rapidity and transience after MCAo.
This pattern is consistent with the concept
that the acute but transient elevation in
chemokine levels initially mobilizes neu-
trophils from bone marrow, and then the
rapidly declining levels facilitate the detec-
tion of local tissue chemokine gradients
required for neutrophil extravasation.
The present data add to the emerging
evidence that systemic immune and in-
flammatory processes contribute to the
pathophysiology of stroke. Experimen-
tal stroke induces marked activation of
the peripheral immune system involving
elevated cytokine and chemokine levels
in peripheral lymphoid organs (Offner
et al., 2006). Correlations between levels
of systemic inflammatory mediators,
such as cytokines and acute-phase reac-
tants, and prognosis in stroke patients
have been shown (Muir et al., 1999;
Smith et al., 2004; Waje-Andreassen et
al., 2005; Rallidis et al., 2006). In the
present study, SAA and IL-6 levels were
markedly elevated early after MCAo and
potentiated by systemic IL-1 challenge,
indicating an aggravated systemic acute-
phase response to MCAo and highlight-
ing the clinical relevance of our data. Pe-
ripheral infections acquired after stroke
are a major complication in stroke pa-
tients (Meisel et al., 2005), and alter-
ations in systemic immune function
may also contribute to this susceptibil-
ity. Depletion of T-lymphocytes in-
duced by sympathetic nervous system activation resulted in an
immunosuppressed state and increased risk of infection after
experimental stroke (Prass et al., 2003). Thus, there may be a
complex series of alterations in peripheral immune pathways
after stroke. Potentiation of these changes by an additional
stimulus, as demonstrated in the present study, may have a
critical impact on acute outcome to stroke and indicates that a
fuller understanding of interactions between systemic im-
mune pathways and the injured brain may uncover novel tar-
gets for stroke therapy. In addition, although we have focused
on the acute response to ischemic brain injury, additional
studies are warranted to investigate the impact of underlying
systemic inflammation/immune activation on postacute re-
parative processes in view of the pleiotropicity of many in-
flammatory mediators.
In summary, the present data support integral roles for IL-1
and neutrophil mobilization in mediating the deleterious effects
of a systemic inflammatory challenge on acute ischemic brain
damage. This mechanistic insight may help to explain the less
favorable response to stroke in patients with preceding infection.
Furthermore, the concept that priming of systemic inflammatory
pathways leads to exacerbated brain damage may have broad
Figure 7. Neutropenia attenuates IL-1-induced exacerbation of ischemic damage. Neutropenia was induced by anti-PMN
antibody treatment before induction of MCAo. Mice were administered vehicle (veh) or IL-1 systemically at the onset of MCAo.
A, Neutrophil depletion significantly abolished the IL-1-induced neutrophilia 24 h after MCAo and also markedly reduced the
number of circulating PMNs in control IgG-treatedmice.MBS-1 immunohistochemistry shows abundant neutrophil accumulation
in the cerebral cortex 24 h after MCAo in response to IL-1 treatment in control IgG-treatedmice (B) but not in neutropenic mice
(C). D, Quantification of MBS-1 immunohistochemistry demonstrated a significant attenuation of the IL-1-induced neutrophil
infiltrate in PMN-depleted mice. E, IL-1 induced a significant threefold increase in ischemic damage. This increase was signifi-
cantly attenuated by70% in neutropenic mice. *p 0.05, **p 0.01, Student’s t test; ‡‡p 0.01 versus IgG plus vehicle,
#p 0.05 versus IgG plus IL-1, one-way ANOVA followed by Student’s t test with Bonferroni’s correction. Data are presented as
mean SEM.F, Representative cresyl violet-stainedbrain sections illustrate a reduction in cortical damage.G, IL-1 significantly
exacerbated neurological deficit, and PMNdepletion significantly reduced the severity of neurological deficit in IL-1-challenged
mice. *p 0.05, Kruskal–Wallis test followed by Dunn’s multiple-comparison test. Bars showmedian. Scale bar, 250m. n
6–7 per group.
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implications for stroke etiology and therapy because themajority
of stroke patients are likely to present with preexisting systemic
inflammation caused by comorbidities such as atherosclerosis
and heart disease.
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